Agenus | AGEN - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.29B 3.9B 2025-12
Agenus USD 323.49M 36.36M 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Celldex Therapeutics USD 50.99M 4.53M 2025-12
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 21.39B 57M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Intrexon USD 23.02M 38K 2024-06
J&J USD 54.13B 3.26B 2025-12
Jiangsu Hengrui CNY 7.85B 4.39B 2025-09
Karyopharm Therapeutics USD 87.16M 12.06M 2025-09
MacroGenics USD 43.11M 1.36M 2025-12
Merck EUR 9.04B 405M 2025-12
Merck USD 28.63B 2.59B 2025-09
Northwest Biotherapeutics USD 87.9M 3.98M 2025-09
Novartis USD 27.28B 4.72B 2025-12
Novavax USD 459.95M 30.08M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Veracyte USD 59.94M 12.22M 2025-12